The Era of Therapeutic Biosimilars Has Arrived: What You Need to Know

Author:
Andrew D. Zelenetz
Search for other papers by Andrew D. Zelenetz in
Current site
Google Scholar
PubMed Close
 MD, PhD
Volume/Issue:
Volume 17: Issue 11.5
Online Publication Date:
Nov 2019
DOI:
https://doi.org/10.6004/jnccn.2019.5036
Restricted access

Although complex, biologic agents are key components of modern therapy in multiple disciplines, particularly oncology. However, despite the fact that biosimilars (eg, filgrastim‐sndz, bevacizumab‐awwb, trastuzumab‐dkst, rituximab-abbs) have been approved in the United States, many clinicians are poorly informed about their unique pathway for approval. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center, outlined important issues regarding the use of biosimilars, including extrapolation, interchangeability, and naming.

Disclosures: Dr. Zelenetz has disclosed that he has received research support from Genentech/Roche, Gilead, MEI, and BeiGene; he has been a consultant for Celegene/JUNO, Genentech/Roche, Gilead, BeiGene, Pharmacyclics, Jansen, Amgen, Astra‐Zeneca, Novartis, and MEI Pharma; and he is on the Scientific Advisory Board of the Lymphoma Research Foundation and Adaptive Biotechnologies.

Correspondence: Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Email: zeleneta@mskcc.org
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Weise M, Bielsky MC, De Smet K, et al. Biosimilars: why terminology matters. Nat Biotechnol 2011;29:690–693.

  • 2.

    U.S. Food and Drug Administration. Guidance Document: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed October 11, 2019.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Lucio SD, Stevenson JG, Hoffman JM. Biosimilars: implications for health-system pharmacists. Am J Health Syst Pharm 2013;70:2004–2017.

  • 4.

    Weise M, Kurki P, Wolff-Holz E, et al. Biosimilars: the science of extrapolation. Blood 2014;124:3191–3196.

  • 5.

    Kim WS, Buske C, Ogura M, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol 2017;4:e362–373.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    U.S. Food and Drug Administration. Guidance Document: Nonproprietary Naming of Biological Products Guidance for Industry. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonproprietary-naming-biological-products-guidance-industry. Accessed October 11, 2019.

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2019 by the National Comprehensive Cancer Network 2019
Page Numbers:
3
Article Category:
Research Article
Print Publication Date:
01 Nov 2019
Online Publication Date:
Nov 2019

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2838 624 144
PDF Downloads 1053 102 5
EPUB Downloads 0 0 0